Jefferies Maintains Buy on Elevance Health, Raises Price Target to $604
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst David Windley maintains a Buy rating on Elevance Health (ELV) and raises the price target from $602 to $604.

April 19, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies maintains a Buy rating on Elevance Health and raises the price target to $604.
The increase in price target by Jefferies reflects a positive outlook on Elevance Health, suggesting confidence in the company's future performance. This analyst endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100